The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study
Preprint
Peto L. et al, (2024)
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15
Community involvement in an outbreak - One year on for mpox.
Journal article
Cheyne A. et al, (2023), Clin Infect Dis
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
Horby PW. et al, (2023)
Randomised controlled trials for mpox in endemic countries.
Journal article
Rojek A. et al, (2023), Lancet Infect Dis
Microbial diversity and antimicrobial resistance in faecal samples from acute medical patients assessed through metagenomic sequencing.
Journal article
Yokoyama M. et al, (2023), PLoS One, 18
Virus Detection and Identification in Minutes Using Single-Particle Imaging and Deep Learning.
Journal article
Shiaelis N. et al, (2022), ACS Nano
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.
Journal article
Peto L. et al, (2022), Adv Biol Regul
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Preprint
RECOVERY Collaborative Group None. et al, (2022)
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
RECOVERY Collaborative Group None. et al, (2022)
Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
RECOVERY Collaborative Group None. et al, (2022)
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2021), The Lancet. Respiratory medicine, 9, 1419 - 1426
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
RECOVERY Collaborative Group None. et al, (2021)
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
RECOVERY Collaborative Group None. et al, (2021)
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Working paper
RECOVERY Collaborative Group None., (2021), Lancet, 397, 2049 - 2059